Feasibility of intravenous vitamin C supplementation in allogeneic hematopoietic cell transplant recipients.

ABSTRACT:

Introduction

Intravenous vitamin C was administered following hematopoietic stem cell transplant to mitigate nonrelapse mortality (NRM) in a Phase II clinical trial.

Methods

Patients with advanced hematologic malignancies received IV vitamin C, 50 mg/kg/day, in three divided doses on days 1-14 after HSCT, followed by 500 mg bid oral until 6 months.

Results

All patients enrolled (55) were deficient in vitamin C at day 0 and had restoration to normal levels. Vitamin C recipients had a trend for lower nonrelapse mortality (NRM, 11% vs. 25%, p-value = 0.07) compared with propensity score-matched historical controls. A similar trend toward improved survival was observed (82% vs. 62% p = 0.06), with no attributable grade 3 and 4 toxicities to vitamin C.

Con

SUBMITTER: Simmons GL 

PROVIDER: S-EPMC11474309 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature